Abstract
The pharmacokinetics and suction-induced blister fluid penetration of cefdinir following single oral administrations of 200, 300, 400, and 600 mg were studied in 16 healthy young male volunteers according to a Latin square design. Plasma, blister, and urine samples were assayed by high-pressure liquid chromatography. We observed a nonlinear relationship (P = 0.02) between the dose and the maximum concentration in plasma as well as between the dose and the area under the concentration-time curve (AUC) in plasma (P < 0.001), which may be indicative of a limited absorption process. This resulted in a lower AUC value than expected as well as a smaller fraction of cefdinir excreted unchanged at a dose of 600 mg. Renal clearance decreased with increasing doses (P < 0.006; analysis of variance with the Latin square design and Games-Howell procedure). Maximal cefdinir concentrations in blister fluid were delayed compared with concentrations in plasma. Blister fluid penetration measured by the ratio of the AUC in blister fluid to the AUC in plasma was extensive (92.4 to 108.4%). Cefdinir concentrations in blister fluid remained equal to or higher than the concentrations in plasma from 6 to 12 h following cefdinir administration. On the basis of the concentrations in blister fluid and the in vitro MIC data, we estimated that cefdinir at 200 to 400 mg administered twice daily would be adequate to treat uncomplicated skin infections caused by Streptococcus pyogenes. Seven volunteers experienced episodes of light-to-moderate diarrhea. These adverse events occurred irrespective of dose.
Full Text
The Full Text of this article is available as a PDF (229.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bergan T. Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis. 1981 Jan-Feb;3(1):45–66. doi: 10.1093/clinids/3.1.45. [DOI] [PubMed] [Google Scholar]
- Briggs B. M., Jones R. N., Erwin M. E., Barrett M. S., Johnson D. M. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):425–434. doi: 10.1016/0732-8893(91)90069-r. [DOI] [PubMed] [Google Scholar]
- Drusano G. L. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl. 1990;74:235–248. [PubMed] [Google Scholar]
- Gerlach E. H., Jones R. N., Allen S. D., Koontz F. P., Murray P. R., Pfaller M. A., Washington J. A., Erwin M. E. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagn Microbiol Infect Dis. 1992 Aug;15(6):537–543. doi: 10.1016/0732-8893(92)90105-3. [DOI] [PubMed] [Google Scholar]
- Inamoto Y., Chiba T., Kamimura T., Takaya T. FK 482, a new orally active cephalosporin synthesis and biological properties. J Antibiot (Tokyo) 1988 Jun;41(6):828–830. doi: 10.7164/antibiotics.41.828. [DOI] [PubMed] [Google Scholar]
- Mine Y., Kamimura T., Watanabe Y., Tawara S., Matsumoto Y., Shibayama F., Kikuchi H., Takaya T., Kuwahara S. In vitro antibacterial activity of FK482, a new orally active cephalosporin. J Antibiot (Tokyo) 1988 Dec;41(12):1873–1887. doi: 10.7164/antibiotics.41.1873. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Saha G., Chin N. X. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother. 1989 Oct;33(10):1795–1800. doi: 10.1128/aac.33.10.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Neill P., Nye K., Douce G., Andrews J., Wise R. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrob Agents Chemother. 1990 Feb;34(2):232–234. doi: 10.1128/aac.34.2.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scriver S. R., Willey B. M., Low D. E., Simor A. E. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens. Eur J Clin Microbiol Infect Dis. 1992 Jul;11(7):646–652. doi: 10.1007/BF01961677. [DOI] [PubMed] [Google Scholar]
- Stone J. W., Linong G., Andrews J. M., Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221–228. doi: 10.1093/jac/23.2.221. [DOI] [PubMed] [Google Scholar]
- Ueno K., Tanaka K., Tsujimura K., Morishima Y., Iwashige H., Yamazaki K., Nakata I. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther. 1993 Nov;54(5):473–475. doi: 10.1038/clpt.1993.178. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Thornber D. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin. J Antimicrob Chemother. 1991 Aug;28(2):239–248. doi: 10.1093/jac/28.2.239. [DOI] [PubMed] [Google Scholar]